These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 11330322)

  • 21. Role of the α Clamp in the Protein Translocation Mechanism of Anthrax Toxin.
    Brown MJ; Thoren KL; Krantz BA
    J Mol Biol; 2015 Oct; 427(20):3340-3349. PubMed ID: 26344833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human antibodies from immunized donors are protective against anthrax toxin in vivo.
    Wild MA; Xin H; Maruyama T; Nolan MJ; Calveley PM; Malone JD; Wallace MR; Bowdish KS
    Nat Biotechnol; 2003 Nov; 21(11):1305-6. PubMed ID: 14555959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Small molecule inhibitors of anthrax toxin-induced cytotoxicity targeted against protective antigen.
    Rubert Pérez C; López-Pérez D; Chmielewski J; Lipton M
    Chem Biol Drug Des; 2012 Mar; 79(3):260-9. PubMed ID: 22146079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fusion protein of Delta 27LFn and EFn has the potential as a novel anthrax toxin inhibitor.
    Kong Y; Guo Q; Yu C; Dong D; Zhao J; Cai C; Hou L; Song X; Fu L; Xu J; Chen W
    FEBS Lett; 2009 Apr; 583(8):1257-60. PubMed ID: 19332063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anthrax protective antigen cleavage and clearance from the blood of mice and rats.
    Moayeri M; Wiggins JF; Leppla SH
    Infect Immun; 2007 Nov; 75(11):5175-84. PubMed ID: 17724066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LRP6 holds the key to the entry of anthrax toxin.
    Bann JG; Cegelski L; Hultgren SJ
    Cell; 2006 Mar; 124(6):1119-21. PubMed ID: 16564002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis of potent inhibitors of anthrax toxin based on poly-L-glutamic acid.
    Joshi A; Saraph A; Poon V; Mogridge J; Kane RS
    Bioconjug Chem; 2006; 17(5):1265-9. PubMed ID: 16984137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of membrane translocation by anthrax protective antigen.
    Wesche J; Elliott JL; Falnes PO; Olsnes S; Collier RJ
    Biochemistry; 1998 Nov; 37(45):15737-46. PubMed ID: 9843379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Where and how do anthrax toxins exit endosomes to intoxicate host cells?
    Puhar A; Montecucco C
    Trends Microbiol; 2007 Nov; 15(11):477-82. PubMed ID: 17983750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of anthrax toxins in dissemination, disease progression, and induction of protective adaptive immunity in the mouse aerosol challenge model.
    Loving CL; Khurana T; Osorio M; Lee GM; Kelly VK; Stibitz S; Merkel TJ
    Infect Immun; 2009 Jan; 77(1):255-65. PubMed ID: 18955474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of Therapeutically Active Molecules against Anthrax through Structure and Ligand based Drug Design.
    Nandi S; Saxena M; Saxena AK
    Curr Top Med Chem; 2018; 18(27):2294-2312. PubMed ID: 30582475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin.
    Lim NK; Kim JH; Oh MS; Lee S; Kim SY; Kim KS; Kang HJ; Hong HJ; Inn KS
    Infect Immun; 2005 Oct; 73(10):6547-51. PubMed ID: 16177329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis of polyvalent inhibitors of controlled molecular weight: structure-activity relationship for inhibitors of anthrax toxin.
    Gujraty KV; Joshi A; Saraph A; Poon V; Mogridge J; Kane RS
    Biomacromolecules; 2006 Jul; 7(7):2082-5. PubMed ID: 16827573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitors of anthrax lethal factor based upon N-oleoyldopamine.
    Gaddis BD; Rubert Pérez CM; Chmielewski J
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2467-70. PubMed ID: 18314330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening inhibitors of anthrax lethal factor.
    Tonello F; Seveso M; Marin O; Mock M; Montecucco C
    Nature; 2002 Jul; 418(6896):386. PubMed ID: 12140548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates.
    Yan M; Roehrl MH; Basar E; Wang JY
    Vaccine; 2008 Feb; 26(7):947-55. PubMed ID: 18192092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. War against anthrax.
    Khanna H; Singh Y
    Mol Med; 2001 Dec; 7(12):795-6. PubMed ID: 11844866
    [No Abstract]   [Full Text] [Related]  

  • 38. Protection from anthrax toxin-mediated killing of macrophages by the combined effects of furin inhibitors and chloroquine.
    Komiyama T; Swanson JA; Fuller RS
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3875-82. PubMed ID: 16127065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Designing a polyvalent inhibitor of anthrax toxin.
    Mourez M; Kane RS; Mogridge J; Metallo S; Deschatelets P; Sellman BR; Whitesides GM; Collier RJ
    Nat Biotechnol; 2001 Oct; 19(10):958-61. PubMed ID: 11581662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble P-selectin rescues mice from anthrax lethal toxin-induced mortality through PSGL-1 pathway-mediated correction of hemostasis.
    Sun DS; Chang YW; Kau JH; Huang HH; Ho PH; Tzeng YJ; Chang HH
    Virulence; 2017 Oct; 8(7):1216-1228. PubMed ID: 28102766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.